{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T19:51:51Z","timestamp":1774122711069,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Shandong Provincial Natural Science Foundation, China","award":["No.ZR2020MH389; ZR2020QH208"],"award-info":[{"award-number":["No.ZR2020MH389; ZR2020QH208"]}]},{"name":"Shandong Medical and Health Technology Development Plan Project","award":["No.202101041037"],"award-info":[{"award-number":["No.202101041037"]}]},{"name":"Jinan clinical medical science and technology innovation plan","award":["No.201907031"],"award-info":[{"award-number":["No.201907031"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Radiation pneumonitis (RP) affects both patients and physicians during radiation therapy for lung cancer. To date, there are no effective drugs for improving the clinical outcomes of RP. The activation of angiotensin-converting enzyme 2 (ACE2) improves experimental acute lung injury caused by severe acute respiratory syndrome coronavirus, acid inhalation, and sepsis. However, the effects and underlying mechanisms of ACE2 in RP remain unclear. Therefore, this study aimed to investigate the effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on RP and ACE2\/angiotensin-(1\u20137)\/Mas receptor pathway activation. We found that radiotherapy decreased the expression of ACE2 and that overexpression of ACE2 alleviated lung injury in an RP mouse model. Moreover, captopril and valsartan restored ACE2 activation; attenuated P38, ERK, and p65 phosphorylation; and effectively mitigated RP in the mouse model. Further systematic retrospective analysis illustrated that the incidence of RP in patients using renin-angiotensin system inhibitors (RASis) was lower than that in patients not using RASis (18.2% vs. 35.8% at 3\u00a0months, <jats:italic>p<\/jats:italic>\u2009=\u20090.0497). In conclusion, the current findings demonstrate that ACE2 plays a critical role in RP and suggest that RASis may be useful potential therapeutic drugs for RP.<\/jats:p>","DOI":"10.1038\/s41598-023-35412-0","type":"journal-article","created":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T10:02:36Z","timestamp":1684836156000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Renin-angiotensin system inhibitors mitigate radiation pneumonitis by activating ACE2-angiotensin-(1\u20137) axis via NF-\u03baB\/MAPK pathway"],"prefix":"10.1038","volume":"13","author":[{"given":"Changsheng","family":"Cong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiying","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinhui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wang","family":"Jing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yawen","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guohai","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yueying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meili","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,23]]},"reference":[{"issue":"3 Suppl","key":"35412_CR1","doi-asserted-by":"publisher","first-page":"S70","DOI":"10.1016\/j.ijrobp.2009.06.091","volume":"76","author":"LB Marks","year":"2010","unstructured":"Marks, L. B. et al. Radiation dose-volume effects in the lung. Int. J. Radiat. Oncol. Biol. Phys. 76(3 Suppl), S70\u2013S76 (2010).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"35412_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.radonc.2015.09.001","volume":"117","author":"N Ebert","year":"2015","unstructured":"Ebert, N., Baumann, M. & Troost, E. G. Radiation-induced lung damage - Clinical risk profiles and predictive imaging on their way to risk-adapted individualized treatment planning. Radiother. Oncol. 117(1), 1\u20133 (2015).","journal-title":"Radiother. Oncol."},{"issue":"24","key":"35412_CR3","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","volume":"379","author":"SJ Antonia","year":"2018","unstructured":"Antonia, S. J. et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N. Engl. J. Med. 379(24), 2342\u20132350 (2018).","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"35412_CR4","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia, S. J. et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N. Engl. J. Med. 377(20), 1919\u20131929 (2017).","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"35412_CR5","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S1470-2045(17)30380-7","volume":"18","author":"N Shaverdian","year":"2017","unstructured":"Shaverdian, N. et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: A secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 18(7), 895\u2013903 (2017).","journal-title":"Lancet Oncol."},{"issue":"9","key":"35412_CR6","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","volume":"5","author":"W Theelen","year":"2019","unstructured":"Theelen, W. et al. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: Results of the PEMBRO-RT phase 2 randomized clinical trial. JAMA Oncol. 5(9), 1276\u20131282 (2019).","journal-title":"JAMA Oncol."},{"issue":"9","key":"35412_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaoncol.2021.2301","volume":"7","author":"SK Jabbour","year":"2021","unstructured":"Jabbour, S. K. et al. Pembrolizumab Plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non-small cell lung cancer: The phase 2 KEYNOTE-799 nonrandomized trial. JAMA Oncol. 7(9), 1\u20139 (2021).","journal-title":"JAMA Oncol."},{"key":"35412_CR8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.lungcan.2020.05.035","volume":"146","author":"HA Jung","year":"2020","unstructured":"Jung, H. A. et al. Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer. Lung Cancer 146, 23\u201329 (2020).","journal-title":"Lung Cancer"},{"issue":"3","key":"35412_CR9","first-page":"219","volume":"43","author":"ML Sun","year":"2020","unstructured":"Sun, M. L., Yang, J. M., Sun, Y. P. & Su, G. H. Inhibitors of RAS might be a good choice for the therapy of COVID-19 pneumonia. Zhonghua Jie He He Hu Xi Za Zhi 43(3), 219\u2013222 (2020).","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"issue":"10229","key":"35412_CR10","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","volume":"395","author":"F Zhou","year":"2020","unstructured":"Zhou, F. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 395(10229), 1054\u20131062 (2020).","journal-title":"Lancet"},{"issue":"10","key":"35412_CR11","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1161\/CIRCRESAHA.120.317015","volume":"126","author":"M Gheblawi","year":"2020","unstructured":"Gheblawi, M. et al. Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: Celebrating the 20th anniversary of the discovery of ACE2. Circ. Res. 126(10), 1456\u20131474 (2020).","journal-title":"Circ. Res."},{"issue":"7047","key":"35412_CR12","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nature03712","volume":"436","author":"Y Imai","year":"2005","unstructured":"Imai, Y. et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 436(7047), 112\u2013116 (2005).","journal-title":"Nature"},{"issue":"8","key":"35412_CR13","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nm1267","volume":"11","author":"K Kuba","year":"2005","unstructured":"Kuba, K. et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat. Med. 11(8), 875\u2013879 (2005).","journal-title":"Nat. Med."},{"issue":"3","key":"35412_CR14","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/SHK.0000000000000633","volume":"46","author":"H Jia","year":"2016","unstructured":"Jia, H. Pulmonary angiotensin-converting enzyme 2 (ACE2) and inflammatory lung disease. Shock 46(3), 239\u2013248 (2016).","journal-title":"Shock"},{"issue":"1","key":"35412_CR15","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1161\/HYPERTENSIONAHA.112.191452","volume":"60","author":"M Iwai","year":"2012","unstructured":"Iwai, M. et al. Possible involvement of angiotensin-converting enzyme 2 and Mas activation in inhibitory effects of angiotensin II type 1 receptor blockade on vascular remodeling. Hypertension 60(1), 137\u2013144 (2012).","journal-title":"Hypertension"},{"issue":"19","key":"35412_CR16","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1093\/eurheartj\/ehaa373","volume":"41","author":"IE Sama","year":"2020","unstructured":"Sama, I. E. et al. Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors. Eur. Heart J. 41(19), 1810\u20131817 (2020).","journal-title":"Eur. Heart J."},{"issue":"5","key":"35412_CR17","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.ijrobp.2018.12.010","volume":"103","author":"M Ghita","year":"2019","unstructured":"Ghita, M. et al. Preclinical evaluation of dose-volume effects and lung toxicity occurring in and out-of-field. Int. J. Radiat. Oncol. Biol. Phys. 103(5), 1231\u20131240 (2019).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"35412_CR18","doi-asserted-by":"publisher","first-page":"108971","DOI":"10.1016\/j.biopha.2019.108971","volume":"115","author":"Q Chen","year":"2019","unstructured":"Chen, Q. et al. Sini decoction ameliorates sepsis-induced acute lung injury via regulating ACE2-Ang (1\u20137)-Mas axis and inhibiting the MAPK signaling pathway. Biomed Pharmacother. 115, 108971 (2019).","journal-title":"Biomed Pharmacother."},{"issue":"5","key":"35412_CR19","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1016\/j.ijrobp.2009.07.1743","volume":"75","author":"SN Ghosh","year":"2009","unstructured":"Ghosh, S. N. et al. Renin-angiotensin system suppression mitigates experimental radiation pneumonitis. Int. J. Radiat. Oncol. Biol. Phys. 75(5), 1528\u20131536 (2009).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"35412_CR20","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.yjmcc.2014.04.007","volume":"72","author":"TA Ramirez","year":"2014","unstructured":"Ramirez, T. A. et al. Aliskiren and valsartan mediate left ventricular remodeling post-myocardial infarction in mice through MMP-9 effects. J. Mol. Cell. Cardiol. 72, 326\u2013335 (2014).","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"1","key":"35412_CR21","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.chest.2019.03.033","volume":"156","author":"AN Hanania","year":"2019","unstructured":"Hanania, A. N., Mainwaring, W., Ghebre, Y. T., Hanania, N. A. & Ludwig, M. Radiation-induced lung injury: Assessment and management. Chest 156(1), 150\u2013162 (2019).","journal-title":"Chest"},{"issue":"4","key":"35412_CR22","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/S0360-3016(01)01713-8","volume":"51","author":"D Antonadou","year":"2001","unstructured":"Antonadou, D. et al. Randomized phase III trial of radiation treatment +\/- amifostine in patients with advanced-stage lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 51(4), 915\u2013922 (2001).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"2","key":"35412_CR23","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/path.1570","volume":"203","author":"I Hamming","year":"2004","unstructured":"Hamming, I. et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol. 203(2), 631\u2013637 (2004).","journal-title":"J. Pathol."},{"key":"35412_CR24","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.yjmcc.2013.11.017","volume":"66","author":"VB Patel","year":"2014","unstructured":"Patel, V. B. et al. Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE\/ADAM-17: A positive feedback mechanism in the RAS. J. Mol. Cell. Cardiol. 66, 167\u2013176 (2014).","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"8","key":"35412_CR25","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1161\/CIRCRESAHA.116.307708","volume":"118","author":"VB Patel","year":"2016","unstructured":"Patel, V. B., Zhong, J. C., Grant, M. B. & Oudit, G. Y. Role of the ACE2\/angiotensin 1\u20137 axis of the renin-angiotensin system in heart failure. Circ Res. 118(8), 1313\u20131326 (2016).","journal-title":"Circ Res."},{"issue":"1","key":"35412_CR26","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s13054-017-1823-x","volume":"21","author":"A Khan","year":"2017","unstructured":"Khan, A. et al. A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Crit. Care. 21(1), 234 (2017).","journal-title":"Crit. Care."},{"key":"35412_CR27","doi-asserted-by":"publisher","first-page":"105292","DOI":"10.1016\/j.phrs.2020.105292","volume":"163","author":"EM Melo","year":"2021","unstructured":"Melo, E. M. et al. Relevance of angiotensin-(1\u20137) and its receptor Mas in pneumonia caused by influenza virus and post-influenza pneumococcal infection. Pharmacol. Res. 163, 105292 (2021).","journal-title":"Pharmacol. Res."},{"key":"35412_CR28","doi-asserted-by":"publisher","first-page":"104350","DOI":"10.1016\/j.yexmp.2019.104350","volume":"113","author":"R Ye","year":"2020","unstructured":"Ye, R. & Liu, Z. ACE2 exhibits protective effects against LPS-induced acute lung injury in mice by inhibiting the LPS-TLR4 pathway. Exp. Mol. Pathol. 113, 104350 (2020).","journal-title":"Exp. Mol. Pathol."},{"key":"35412_CR29","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.biopha.2016.05.025","volume":"82","author":"X Yu","year":"2016","unstructured":"Yu, X. et al. Tetrahydroberberrubine attenuates lipopolysaccharide-induced acute lung injury by down-regulating MAPK, AKT, and NF-\u03baB signaling pathways. Biomed. Pharmacother. 82, 489\u2013497 (2016).","journal-title":"Biomed. Pharmacother."},{"issue":"4","key":"35412_CR30","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1124\/pr.118.017129","volume":"71","author":"LB Arendse","year":"2019","unstructured":"Arendse, L. B. et al. Novel therapeutic approaches targeting the renin-angiotensin system and associated peptides in hypertension and heart failure. Pharmacol. Rev. 71(4), 539\u2013570 (2019).","journal-title":"Pharmacol. Rev."},{"issue":"10","key":"35412_CR31","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jchf.2020.06.020","volume":"8","author":"KF Docherty","year":"2020","unstructured":"Docherty, K. F., Vaduganathan, M., Solomon, S. D. & McMurray, J. Sacubitril\/Valsartan: Neprilysin inhibition 5 years after PARADIGM-HF. JACC Heart Fail. 8(10), 800\u2013810 (2020).","journal-title":"JACC Heart Fail."},{"issue":"1","key":"35412_CR32","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ijrobp.2011.11.013","volume":"84","author":"J Kharofa","year":"2012","unstructured":"Kharofa, J., Cohen, E. P., Tomic, R., Xiang, Q. & Gore, E. Decreased risk of radiation pneumonitis with incidental concurrent use of angiotensin-converting enzyme inhibitors and thoracic radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 84(1), 238\u2013243 (2012).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"3","key":"35412_CR33","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.cllc.2015.08.007","volume":"17","author":"S Bracci","year":"2016","unstructured":"Bracci, S. et al. Renin-angiotensin system inhibitors might help to reduce the development of symptomatic radiation pneumonitis after stereotactic body radiotherapy for lung cancer. Clin. Lung Cancer. 17(3), 189\u2013197 (2016).","journal-title":"Clin. Lung Cancer."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35412-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35412-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35412-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T10:13:11Z","timestamp":1684836791000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35412-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,23]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["35412"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-35412-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,23]]},"assertion":[{"value":"19 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8324"}}